This specificity implies that YTHDF1-targeted therapies could selectively disrupt CSC self-renewal without broadly affecting normal stem cells in the colon, a critical consideration for minimizing toxicity in CRC treatment. Here, YTHDF1 is linked to colorectal carcinoma.